810 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Trust Asset Management LLC

Trust Asset Management LLC acquired a new position in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 810 shares of the medical instruments supplier’s stock, valued at approximately $211,000.

A number of other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. grew its position in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the last quarter. Friedenthal Financial purchased a new position in shares of Insulet in the 4th quarter worth approximately $57,000. TD Private Client Wealth LLC boosted its stake in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the period. Finally, Versant Capital Management Inc increased its position in Insulet by 106.1% during the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after acquiring an additional 157 shares during the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $275.81 on Tuesday. The company’s 50 day moving average is $266.30 and its 200 day moving average is $233.51. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market cap of $19.35 billion, a price-to-earnings ratio of 47.23, a PEG ratio of 3.46 and a beta of 1.22. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.77.

Insider Activity

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PODD shares. Wells Fargo & Company raised their target price on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. TD Cowen upped their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Canaccord Genuity Group raised their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. BTIG Research upped their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $272.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.